Credit: Canva
Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, and go beyond their usual boundaries to invade adjoining parts of the body. According to the World Health Organization (WHO), it is the second most common cause of death globally, accounting for millions of deaths every year. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer are the most common among women. However, these are not necessarily the deadliest forms of cancer.
What makes cancer the deadliest depends upon how many people have it and what percentage of those people actually survive. Cancer researchers determine this on the basis of five-year relative survival. This is the percentage of people who are expected to survive the effects of a given cancer, excluding their risk of other possible causes of death, for five years past a diagnosis. It is also important to note that what makes cancer really deadly is that practically no cure for it. A cure for cancer would imply that there are no cancerous cells remaining in the body.
Here are the 5 deadliest cancers in the U.S., according to SEER five-year relative survival data for cases diagnosed between 2014 and 2020.
1. Pancreatic cancer occurs when cells in your pancreas, a gland in your abdomen that aids digestion, mutate and multiply out of control, forming a tumour. Major risk factors include smoking, obesity, diabetes, chronic pancreatitis, certain genetic mutations and environmental chemical exposure.
2. Esophageal cancer develops in the oesophagus, which is the tube that connects your throat to your stomach.
3. Liver cancer and intrahepatic bile duct cancer originate in the liver or bile ducts, often linked to hepatitis infections, heavy alcohol use, obesity, and aflatoxin exposure.
4. Lung and bronchus cancer primarily caused by smoking, secondhand smoke, and environmental pollutants, affects the lungs and airways, making it the leading cause of cancer death in the US.
5. Acute myeloid leukaemia (AML) is an aggressive blood and bone marrow cancer that progresses rapidly, often linked to genetic mutations, radiation exposure, and certain chemicals.
ALSO READ: Why Are Lifestyle Factors Making Millennials Vulnerable To Cancer?
Credits: Canva
Alzheimer’s patients have received discouraging news after the release of results from a major study. Novo Nordisk confirmed that its Alzheimer’s treatment did not show a “statistically significant” slowdown in the progression of the illness. Two trials evaluating the company’s weight loss medicine semaglutide in Alzheimer’s disease did not meet their targets, the firm said on Monday, as the drug failed to slow decline compared with a placebo.
Testing semaglutide, the active ingredient in Ozempic and Wegovy, for Alzheimer’s had always been viewed as a high-risk attempt, even though research has suggested the drug may influence several processes beyond metabolism. Still, Novo had raised interest in recent weeks by advertising roles connected to Alzheimer’s consumer marketing and medical affairs.
Novo Nordisk said on Monday that an older oral form of semaglutide did not achieve its main outcome in late-stage trials assessing whether the drug could reduce cognitive decline in people with Alzheimer’s disease, sending its shares down by 10 percent.
The development dims expectations that Alzheimer’s could become a major new area for GLP-1 medicines like semaglutide, at a time when Novo is facing stronger competition for its leading products in obesity and diabetes. Treatment choices for Alzheimer’s patients remain limited. The company’s study had been closely followed as a potential sign of whether GLP-1 drugs, widely used for diabetes and weight control, might slow the condition’s advance.
The pill tested was Rybelsus, approved only for type 2 diabetes and containing semaglutide, as reported by Reuters.
The firm’s Executive Vice President for Product and Portfolio Strategy, Ludovic Helfgott, had earlier described the Alzheimer’s trials as a “lottery ticket,” reflecting both the uncertainty and the considerable promise involved. Alzheimer’s and related dementias affect more than 55 million people worldwide, and no cure exists. “While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer’s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities,” Chief Scientific Officer Martin Holst Lange said in a statement.
The findings from the two early-stage studies, EVOKE and EVOKE+, mark another setback for the Danish company and its new CEO Mike Doustdar. Novo had experienced remarkable success with Ozempic and Wegovy, but slower sales growth and a sharp drop in its stock value led to a leadership shift and significant job cuts.
The disappointment adds weight to analysts’ doubts about Novo’s Alzheimer’s plans, with UBS having earlier estimated only a 10 percent likelihood of success.
Alzheimer’s, marked by deep cognitive decline, fading memory and changes in behaviour, remains one of the hardest challenges in drug research. Novo had repeatedly acknowledged the uncertainty surrounding these studies. Even so, the possible payoff was significant. Analysts at Morgan Stanley had estimated that a breakthrough could have added up to $5 billion in yearly revenue.
“We believed it was important to assess whether semaglutide could offer any benefit,” Chief Scientific Officer Martin Holst Lange said, referring to the drug better known as Ozempic. The treatment did show improvement in certain biological markers connected to Alzheimer’s, but these gains did not lead to a slower progression of the condition.
The company is also working to strengthen its footing in the obesity sector. Any sign that Wegovy could influence the most common form of dementia might have provided an edge over Eli Lilly’s Zepbound in the United States, where competition in this field is intensifying.
Credits: Canva
Delhi residents are once again dealing with heavy pollution as a dense layer of smog covered the city on November 22. In response to the worsening situation, the Commission for Air Quality Management (CAQM) on Saturday put GRAP Stage IV curbs into force, as several monitoring stations across the Capital recorded air in the ‘severe’ category.
Under the updated rules, the Government of National Capital Territory of Delhi and the NCR state administrations will decide whether public, municipal and private offices should function with only half their staff on site, with the remaining employees working from home. CAQM noted in its latest advisory, “CAQM has revised the GRAP schedule on 21.11.2025 to make it more stringent thus preventing further deterioration of air quality in Delhi-NCR.”
As per CAQM, the following GRAP 4 steps will now be implemented during GRAP 3:
Since GRAP 3 remains active in Delhi, activities such as non-essential construction, demolition work, and the use of older vehicle categories, including those below the Bharat Stage (BS)-IV emission norms, continue to be limited. People have been advised to minimise time spent outdoors, especially during the early mornings and late evenings when pollution is often at its peak. On Friday, the Delhi government also directed schools and other educational institutions to halt all sports and outdoor physical activities.
GRAP follows four levels, each tied to the Air Quality Index (AQI) at the time.
Stage I of GRAP begins when air quality reaches the “poor” range (AQI between 201 and 300, which can cause breathing discomfort after prolonged exposure).
Stage II is enforced when air turns “very poor” (AQI between 301 and 400, which can result in respiratory issues with continued exposure).
Stage III comes into effect when pollution becomes “severe” (AQI between 401 and 500, a level at which even healthy individuals may feel the impact and those with existing conditions face serious health risks).
Stage IV of GRAP is declared when pollution crosses into the “severe+” range (AQI above 500).
India’s national AQI framework, created by the Central Pollution Control Board (CPCB), categorises air quality based on its potential impact on health, ranging from mild discomfort to significant respiratory and heart-related problems.
Each stage of GRAP includes a fixed set of actions for authorities to follow. As pollution increases and GRAP moves to the next stage, measures from earlier levels continue. This creates a step-by-step response system designed to slow down the rise in pollution and prevent conditions from becoming even more harmful.
At the moment, GRAP III is in force in Delhi, as air quality has been shifting between the ‘severe’ and ‘very poor’ bands. A range of restrictions linked to this stage is already being implemented across the city.
Credits: Gemini
As Delhi’s air grows heavier with pollution, citizens have begun stepping out in protest to raise their concerns. During a demonstration at the C Hexagon near India Gate, some protestors allegedly sprayed chilli solution on police officers, disrupted official duties and blocked traffic, according to the police. New Delhi DCP Devesh Kumar Mahla stated that this was the first time such a substance had been used against officers during an agitation. “For the first time, we witnessed chilli spray being used on police personnel. A few officers were hit in the eyes and are receiving care at RML Hospital. Legal action is underway,” the Delhi Police official told The Print.
This raises an important question. How harmful can a chilli spray actually be? Can spraying it put a person’s organs at risk? Here is a closer look.
Chilli spray, often known as pepper spray, is produced from oleoresin capsicum (OC), an oily extract taken from chilli peppers. Its main active compound is capsaicin, the same substance that gives chillies their heat, only in a far more concentrated and weaponised form.
The OC is mixed into a liquid base (such as water with an emulsifier like propylene glycol, or an alcohol solution) and is then pressurised so it can be dispersed as a fine aerosol spray, according to The Wire Science.
When pepper spray reaches the eyes, it brings on sudden eyelid closure, sharp pain and temporary loss of vision. Many describe the sensation as burning, bubbling or boiling, along with intense discomfort, as per Medical News Today.
It may also lead to:
Chilli spray affects your airways by provoking strong inflammation and irritation of the moist lining inside the nose, throat, and lungs. Capsaicin is the key driver of this reaction, and it can spark a wide set of breathing symptoms. In more serious instances, it may even lead to complications.
The eyes react almost instantly to pepper spray. It causes heavy tearing, swelling, redness, stinging and momentary blindness. The cornea’s surface layer becomes disturbed, which means people with conditions like diabetes, dry eyes or recurrent corneal erosion may experience stronger effects than someone with healthy eyes, as reported by Medical News Today.
Anyone wearing contact lenses should remove them at once using clean fingers that have not touched the spray. The lenses must be thrown away because they cannot be salvaged.
Rubbing the eyes will make the pain far worse and should be avoided. Rinsing gently with saline can help. Blinking repeatedly also assists in washing the irritant out with tears.
After being exposed to pepper spray, these steps can help shorten the discomfort:
© 2024 Bennett, Coleman & Company Limited